Artificial Intelligence
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to August 3, 2023
MIAMI, July 03, 2023 (GLOBE NEWSWIRE) — Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that its sponsor, Vision Sensing, LLC, deposited $72,562.86 into the Company’s trust account on June 30, 2023, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from July 3, 2023 to August 3, 2023 (the “Extension”). The Company has issued to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $72,562.86 as consideration for the funding. This is the third of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on May 1, 2023.
The Extension provides the Company with additional time to complete its initial business combination (the “Business Combination”) with Newsight Imaging Ltd., an Israeli company (“Newsight”), and Newsight MergerSub, Inc., a Delaware corporation and wholly-owned subsidiary of Newsight (“Merger Sub”), pursuant to a business combination agreement dated August 30, 2022 (as it may be amended and/or restated from time to time, the “Business Combination Agreement”), pursuant to which: (i) Merger Sub will merge into the Company resulting in the Company becoming a wholly-owned subsidiary of Newsight, (ii) Newsight will register as a publicly traded company, (iii) Newsight’s existing shares will be split to facilitate a fully diluted value per Newsight share of US$10.00, (iv) the Company’s common stock will be exchanged on a one-for-one basis for Newsight Ordinary Shares and (v) warrants to purchase the Company’s common stock will instead become eligible to purchase the same number of Newsight Ordinary Shares at the same exercise price and for the same exercise period (such transactions, the “Business Combination”). The combined company’s common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol “NSIM”.
About Newsight Imaging
Newsight Imaging develops advanced CMOS image sensor chips for 3D machine vision and spectral analysis. Newsight’s depth camera sensors for machine vision serve verticals such as Mobile & Metaverse, Robotics, Industry 4.0 and Automotive Safety. The Company recently launched its innovative solid-state LiDAR reference design, the eTOF™ LiDAR, based on the NSI1000 sensor. In addition, Newsight has developed its spectral chip backed by AI technology that has multiple uses in rapid pathogen detection and in continuous, condition-based monitoring of fluid flows, including water quality. Newsight’s Virusight subsidiary’s SpectraLIT™ offers a targeted and cost-effective solution for remote healthcare, real time diagnosis, and quality inspection solutions for water and food & beverage, including COVID detection under certain circumstances in less than 20 seconds with 96% accuracy. Newsight’s Watersight subsidiary’s AquaRing provides real-time, AI-based monitoring of flow systems or processes, including installations for water quality monitoring, The Company has US and EU patents and has received multiple grants by the Israeli Innovation Authority. For more information visit www.newsight.com.
About Vision Sensing Acquisition Corp.
Vision Sensing Acquisition Corp. (“VSAC”) is a Special Purpose Acquisition Company (“SPAC”) that has been established to focus on the acquisition of vision sensing technologies (“VST”) including hardware solutions (chips / modules / systems), related application software, artificial intelligence and other peripheral technologies that assist to integrate and/or supplement VST applications. For more information visit www.vision-sensing.com.
Forward-Looking Statements
This press release is provided for informational purposes only and contains information with respect to a proposed business combination (the “Proposed Business Combination”) among VSAC and Newsight. No representations or warranties, express or implied are given in, or in respect of, this press release. In addition, this press release does not purport to be all-inclusive or to contain all the information that may be required to make a full analysis of the Proposed Business Combination.
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. VSAC’s and Newsight’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, VSAC’s and Newsight’s expectations with respect to future performance and anticipated financial impacts of the transactions (the “Transactions”) contemplated by the Business Combination Agreement. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside of the control of VSAC or Newsight and are difficult to predict. Factors that may cause such differences include but are not limited to: (i) the expected timing and likelihood of completion of the Transactions, (ii) the occurrence of any event, change or other circumstances that could give rise to a failure of the conditions to or the termination of the Business Combination Agreement; (iii) the ability of Newsight to meet Nasdaq listing standards following the Transactions and in connection with the consummation thereof; (iv) the occurrence of a material adverse change with respect to the financial position, performance, operations or prospects of Newsight or VSAC; (v) failure to realize the anticipated benefits of the Proposed Business Combination or risk relating to the uncertainty of any prospective financial information of Newsight; (vi) the failure of Newsight to meet projected development and production targets; (vii) the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors, and (viii) other risks and uncertainties described herein and other reports and other public filings with the SEC by VSAC, including VSAC’s Form 10-K for the year ended December 31, 2022 as filed with the SEC on March 24, 2023 (the “10-K”) and its most recent Form 10-Q, as fled with the SEC on May 15, 2023 (the “10-Q”), or that Newsight has filed or intends to file with the SEC, including in the Registration Statement. The foregoing list of factors is not exclusive. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. There may be additional risks that neither VSAC nor Newsight presently know, or that VSAC and Newsight currently believe are immaterial, that could cause actual results to differ from those contained in the forward-looking statements. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. To the fullest extent permitted by law in no circumstances will Newsight, VSAC or any of their respective subsidiaries, interest holders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this press release, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. These forward-looking statements should not be relied upon as representing VSAC’s and Newsight’s assessments as of any date subsequent to the date of this press release. VSAC and Newsight undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
Additional Information About the Proposed Business Combination and Where to Find It
In connection with the Proposed Business Combination, Newsight has filed relevant materials with the SEC, including an Amendment No. 3 to Registration Statement on Form F-4, which includes a preliminary proxy statement/prospectus of VSAC, and a prospectus for the registration of Newsight securities in connection with the Proposed Business Combination (the “Registration Statement”). The Registration Statement has not yet been declared effective. The parties urge its investors, shareholders, and other interested persons to read, when available, the preliminary proxy statement/prospectus and definitive proxy statement/prospectus, in each case when filed with the SEC and documents incorporated by reference therein because these documents will contain important information about VSAC, Newsight and the Proposed Business Combination. After the Registration Statement is declared effective by the SEC, the definitive proxy statement/prospectus and other relevant documents will be mailed to the shareholders of VSAC as of the record date in the future to be established for voting on the Proposed Business Combination and will contain important information about the Proposed Business Combination and related matters. Shareholders of VSAC and other interested persons are advised to read, when available, these materials (including any amendments or supplements thereto) because they will contain important information about VSAC, Newsight and the Proposed Business Combination. Shareholders and other interested persons will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other relevant materials in connection with the Proposed Business Combination, without charge, once available, at the SEC’s website at www.sec.gov or by directing a request to: VSAC Acquisition Corp., Attention: Garry Stein, telephone: +852 9858 0029. The information contained on, or that may be accessed through, the websites or links referenced in this press release in each case is not incorporated by reference into, and is not a part of, this press release.
Participants in the Solicitation
VSAC, Newsight and their respective directors and executive officers may be deemed participants in the solicitation of proxies from VSAC’s shareholders in connection with the Proposed Business Combination. VSAC’s shareholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of VSAC, or persons who may under SEC rules be deemed in the solicitation of proxies to VSAC’s shareholders in connection with the Proposed Business Combination, in the Registration Statement or in VSAC’s Form 10-K or its Form 10-Q. Additional information regarding the interests of such persons are likewise included in that Registration Statement. You may obtain free copies of these documents as described above.
Non-Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Business Combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.
Investor Relations Contact:
Chris Tyson
MZ North America
[email protected]
949-491-8235
Newsight Imaging Contact:
[email protected]
Artificial Intelligence
Clinical Trial Analytics Services Market Projected to Reach $11.95 billion by 2030 – Exclusive Report by 360iResearch
PUNE, India, April 30, 2024 /PRNewswire/ — The report titled “Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization & Dashboarding, Patient Recruitment & Retention Analytics), Stages, End-User, Deployment – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $5.42 billion in 2023 to reach $11.95 billion by 2030, at a CAGR of 11.93% over the forecast period.
“Global Expansion and Technological Advancements in Analytics Services”
Clinical trial analytics services are revolutionizing the landscape of medical research and drug development across the globe by utilizing cutting-edge data analytics and statistical methodologies to offer invaluable insights from clinical trial data. These services enhance trial efficiency, streamline costs, and boost accuracy, enabling stakeholders to refine study protocols, improve patient recruitment measures, ensure participant safety, and conduct in-depth effectiveness studies. Such analytics are pivotal in supporting clinical development strategies, facilitating smoother regulatory approvals, and aiding in ongoing market surveillance and informed decision-making. Challenges such as data privacy concerns and the substantial investments required, the sector continues to grow, driven by an increasing focus on advancing drug discoveries and the sheer volume of clinical trials. The Americas lead the market with robust clinical trial activity, supported by Europe’s push for more transparent and unified trial regulations. Meanwhile, the Middle East is emerging as a key player with significant healthcare investments, and the Asia Pacific region is recognized for its cost advantages and substantial patient demographics, becoming an attractive locale for clinical research organizations (CROs) and pharmaceutical advancements. This global momentum towards personalized medicine and heightened technology integration signifies a promising future for clinical trial analytics services in enhancing the efficacy and outcomes of clinical trials worldwide.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“Revolutionizing Clinical Trials through Analytics: A New Era in Drug Discovery”
The pharmaceutical market is witnessing a significant transformation, marked by an increased focus on developing treatments for a broader spectrum of diseases, including those once deemed untreatable. This shift has propelled the expansion of clinical trials, which are now more complex due to advanced technologies, the inclusion of varied patient demographics, and stringent regulatory standards. As a result, managing and analyzing the vast amounts of data from these clinical trials has become a daunting task. Enter clinical trial analytics services, a game-changing solution that streamlines the management of these trials. These services offer indispensable insights for making strategic decisions, facilitating patient recruitment, ensuring regulatory compliance, and evaluating market potential, ultimately speeding up the delivery of new therapies. With the pharmaceutical sector’s deep investment in the quest for innovative treatments, the pivotal role of clinical trial analytics services in enhancing efficiency and driving success in drug development is clearer than ever.
“Revolutionizing Drug Development: The Power of Clinical Data Analytics”
Clinical data analytics plays a pivotal role in transforming drug development by meticulously analyzing information gathered during clinical trials. This process is key to unlocking valuable insights that lead to better clinical decisions, enhanced trial efficiency, and faster path to market for new treatments. It effectively decodes patterns, forecasts results, and elevates patient care by watching over potential adverse impacts closely. The compilation of a wide variety of data, ranging from patient demographics, clinical outcomes, to biomarkers, underpins these analytics. Innovative technologies including machine learning and artificial intelligence are at the forefront of dissecting these complex data sets to offer understandable insights. The cornerstone of this endeavor is maintaining supreme data quality, ensuring the conclusions drawn are solid and dependable. Clinical trial data management plays an instrumental role, orchestrating the collection, integration, and validation of data throughout its lifecycle. This meticulous process involves designing data capturing systems, setting standards for data collection, and closely monitoring to uphold the integrity of data. Additionally, the blueprinting and vigilant monitoring of clinical trials are critical, demanding clear goals, precise sample sizes, and thorough oversight to guarantee trial integrity and participant safety. Engaging patients in the trial process further underscores the focus on patient-centered approaches, ensuring trials are not just about data but also about the individuals who make the research possible.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“IQVIA Inc. at the Forefront of Clinical Trial Analytics Services Market with a Strong 10.57% Market Share”
The key players in the Clinical Trial Analytics Services Market include Laboratory Corporation of America Holdings, SGS S.A., QIAGEN N.V., ICON PLC, IQVIA Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Clinical Trial Analytics Services Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Analytics Services Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Clinical Trial Analytics Services Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/clinical-trial-analytics-services
“Dive into the Clinical Trial Analytics Services Market Landscape: Explore 184 Pages of Insights, 574 Tables, and 26 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsClinical Trial Analytics Services Market, by ServicesClinical Trial Analytics Services Market, by ComponentClinical Trial Analytics Services Market, by StagesClinical Trial Analytics Services Market, by End-UserClinical Trial Analytics Services Market, by DeploymentAmericas Clinical Trial Analytics Services MarketAsia-Pacific Clinical Trial Analytics Services MarketEurope, Middle East & Africa Clinical Trial Analytics Services MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/clinical-trial-analytics-services
Related Reports:
Clinical Trial Support Services Market – Global Forecast 2024-2030In Silico Clinical Trials Market – Global Forecast 2024-2030Clinical Trial Supplies Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo: https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clinical-trial-analytics-services-market-projected-to-reach-11-95-billion-by-2030—exclusive-report-by-360iresearch-302131960.html
Artificial Intelligence
Synthetik Applied Technologies LLC announces development of UrbanScale – a modeling platform for the prediction, characterization, and quantification of extreme urban heat
AUSTIN, Texas and LONDON, April 30, 2024 /PRNewswire/ — Synthetik Applied Technologies announces the development of UrbanScale, a tool to model and predict effects of extreme heat in urban areas, through a project funded by the National Oceanic and Atmospheric Association (NOAA). The physical characteristics of urban areas amplify heat effects resulting in what are known as urban heat islands — areas where surface temperatures are much higher than their surroundings. The UrbanScale tool addresses this climate peril with sophisticated analytic tools based on physics informed neural networks and cutting-edge machine learning to predict urban heat and help better understand and mitigate the risks associated with these extreme heat events. As a result of climate change, these events are expected to increase, impacting both the people that live in urban areas and the infrastructure on which they depend.
The UrbanScale platform shows significant promise to provide data on the severity of heat islands and their effects to better understand how they impact human health, energy use and damage to physical infrastructure. This information will provide a step-change in capability for government agencies, urban planners, and transportation authorities to direct efforts for mitigation and intervention. In particular, inclusion of demographic information into data pipelines will allow understanding of how urban heat effects may impact vulnerable or disadvantaged populations. Integration with climate forecasts and models will also provide unprecedented capabilities for forecasting risk associated with climate change.
Josh Hatfield, Director of Research and Development at Synthetik, said:
‘We are extremely grateful for the opportunity to study such an important issue. Extreme heat is already the largest cause of weather-related fatalities in the US, and climate change will only increase the importance of understanding heat in urban environments. Helping to meet that challenge fits directly into Synthetik’s mission.’
Synthetik COO Tim Brewer commented:
‘The UrbanScale tool will allow both our government and insurance partners to better characterize the risk of extreme heat in urban centers and promises to deliver critical insight on the way these events impact energy demands. We look forward to exploring its wide-ranging applications.’
Synthetik plans further development of UrbanScale with NOAA and other partners in the public and private sector.
For all inquiries: Contact Synthetik Applied Technologies PR [email protected]
Logo – https://mma.prnewswire.com/media/2067510/Synthetik_Applied_Technologies_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/synthetik-applied-technologies-llc-announces-development-of-urbanscale–a-modeling-platform-for-the-prediction-characterization-and-quantification-of-extreme-urban-heat-302132016.html
Artificial Intelligence
GLiNTECH – a Valiantys company, wins Atlassian Partner of the Year 2023 Services (APAC) award. Valiantys and GLiNTECH declared Finalists for Team Excellence and ITSM Solutions
PARIS, April 30, 2024 /PRNewswire/ — Atlassian announced today that GLiNTECH – a Valiantys company has won the Atlassian Partner of the Year 2023 Services (APAC) award. Valiantys and GLiNTECH were further declared finalists for the Team Excellence and ITSM Solutions awards, respectively.
This is an acknowledgement of their outstanding work for Atlassian customers during the calendar year 2023. This includes exceptional efforts in developing new business and driving innovative solutions for customer success.
“Our industry leading partners play a vital role in our customers’ continued success. We’re honored to highlight our top partners as award finalists this year, reflecting their ongoing commitment to delivering innovative solutions and unparalleled Atlassian services globally,” said Ko Mistry, Atlassian’s Head of Global Channels.
“We are delighted to be named as finalists for these awards from Atlassian, and we are particularly proud to celebrate GLiNTECH’s achievement in winning the Services (APAC) award.” said Emmanuel Benoit, Global Chief Executive Officer, Valiantys. “At Valiantys, embracing diversity of thought and challenging the ways our teams work has always provided Valiantys with a competitive edge to consistently deliver tangible results and value. We look to the future with unwavering determination and confidence as we continue to drive innovation and unlock potential for our customers around the globe.”
“We dedicate our IT Consulting Services and Custom Solutions to fulfilling our customers’ needs for success,” commented Dimitri Spyridopoulos, Chief Executive Officer GLiNTECH – a Valiantys company. “It’s an honor to be recognized by Atlassian as a finalist in two categories that reflect these efforts: Services and ITSM Solutions, and to be declared as winner for the Services award (APAC).”
For more information regarding this Press Release, contact: [email protected]
About Valiantys
Valiantys is a leading global consulting and services firm dedicated to Atlassian. The company accelerates business transformation by digitizing processes and modernizing teamwork, using the best agile methods and tools. Its Atlassian technical expertise is unparalleled and Valiantys supports its customers across the entire spectrum of projects on those platforms. As a recognized Agile at Scale, ITSM, and Cloud Specialized Partner, Valiantys help organizations accelerate time to value with Agile at scale, cloud, and ITSM implementations. Because teamwork requires more than just tools, the firm bridges the gap between applications and strategic practices such as SAFe® and ITIL. Over the last 15 years, Valiantys has helped more than 5,000 customers achieve their desired business outcomes at a reduced time to value, through improved team collaboration. More information about Valiantys can be found at https://www.valiantys.com/
About GLiNTECH – a Valiantys Company
GLiNTECH is a renowned Atlassian Platinum Partner headquartered in Australia and is the preferred choice for over 300 leading brands. The company has amassed more than 20 years of experience servicing enterprise clients across the Asia Pacific region, earning Atlassian Partner of the Year five times, including most recently for Professional Services. GLiNTECH is recognized as a Specialized Atlassian Cloud and ITSM partner. The company offers deep expertise in Licensing, Training, Support, Managed Services, Consulting, and Agile methodologies and has a proven record in providing reliable solutions while driving success within the Atlassian ecosystem. More information about GLiNTECH can be found here: https://www.glintech.com/
GLiNTECH was acquired by Valiantys in February 2024.
Photo – https://mma.prnewswire.com/media/2397508/GLiNTECH_2023_Services_award.jpg Logo – https://mma.prnewswire.com/media/1980997/Valiantys_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/glintech—a-valiantys-company-wins-atlassian-partner-of-the-year-2023-services-apac-award-valiantys-and-glintech-declared-finalists-for-team-excellence-and-itsm-solutions-302127386.html
-
Uncategorized6 days agoCherrypicks Partners with AWS DevAx Leading Cloud Technology Innovation for Hong Kong Enterprises
-
Artificial Intelligence5 days agoHikvision redefines urban mobility with AIoT-powered solutions at Intertraffic 2024
-
Artificial Intelligence5 days agoHITACHI ACQUIRES MA MICRO AUTOMATION OF GERMANY IN EFFORT TO ACCELERATE GLOBAL EXPANSION OF ROBOTIC SI BUSINESS IN THE MEDICAL AND OTHER FIELDS
-
Artificial Intelligence5 days ago
Greater efforts urged on sci-tech cooperation
-
Artificial Intelligence5 days agoWeb O.No: Metaverse and Web 3.0 stunted by internet chaos, warn 87% of business leaders
-
Uncategorized5 days ago
Xiao-I Corporation to Announce Full Year 2023 Results
-
Artificial Intelligence4 days agoCognitive Security Market Projected to Reach $134.26 billion by 2030 – Exclusive Report by 360iResearch
-
Artificial Intelligence5 days ago
IBM, Government of Canada, Government of Quebec Sign Agreements to Strengthen Canada’s Semiconductor Industry
